Ubs Oconnor LLC Verastem, Inc. Transaction History

Ubs Oconnor LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.33 - $10.44 $106,398 - $3.37 Million	-322,421 Reduced 36.26%	566,723 $0
Q3 2022 Nov 14, 2022	SELL	$0.92 - $11.16 $494,811 - $6 Million	-537,839 Reduced 37.69%	889,144 $756 Million
Q2 2022 Aug 12, 2022	BUY	$1.02 - $1.83 $802,722 - $1.44 Million	786,983 Added 122.97%	1,426,983 $1.66 Million
Q1 2022 May 16, 2022	BUY	$1.06 - $2.1 $466,400 - $924,000	440,000 Added 220.0%	640,000 $902,000
Q4 2017 Feb 14, 2018	BUY	$2.99 - $4.85 $598,000 - $969,999	200,000	200,000 $0

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.